SANTHERA RAISES CHF 25 MILLION (€16 MILLION) VIA A FURTHER CLOSING OF ITS 2005 B FINANCING ROUND

Santhera Pharmaceuticals AG ("Santhera"), a Swiss-based biopharmaceutical company focused on neuromuscular diseases, announced today that it has successfully raised CHF 25 million (€ 16 million) via a further closing of the private B financing round which took place earlier in 2005. The new shares have been fully subscribed by the company's existing investors which supported the formation of Santhera Pharmaceuticals via the merger of Graffinity Pharmaceuticals AG (Heidelberg, Germany) and Myocontract AG (Basel, Switzerland) in July 2004.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/5ab20c6d31fafcd99f5c3c9077c26ff3.html)